Peripheral T-cell lymphoma, not otherwise specified

This trial is testing an experimental drug called FG-M131 in people with a type of blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. FG-M131 is designed to target and destroy cancerous T cells that carry a marker called TRBC1, …

This Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…

This early-phase trial is testing whether the experimental drug zeprumetostat, which blocks a protein called EZH2, can work together with either another targeted drug (golidocitinib) or a standard chemotherapy regimen (GemOx) to shrink tumors in people with a rare and aggressive …

This trial is testing whether adding an experimental targeted drug, SHR2554, to standard chemotherapy (liposomal mitoxantrone) can improve outcomes for people with peripheral T-cell lymphoma (PTCL) who have not yet been treated. The study involves about 44 adults with certain PTC…

This early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…

This study tests a new drug called TR115 in about 180 adults with a rare blood cancer (T/NK-cell lymphoma) that has come back or not responded to prior treatments. Participants will receive either TR115 or one of several standard drugs. The main goal is to see if TR115 can slow c…

This phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The st…

This study tests a new approach for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Doctors will use genetic testing of the tumor to choose a personalized combination of drugs, including an experimental drug called zeprumetostat. The goal is to…

This study tests a new drug called BR101801 in 44 people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the dru…

This study tests a drug called SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who have responded to initial treatment. The goal is to see if taking this pill can help keep the cancer from progressing for longer. About 30 adults who have achieved compl…

This study will follow 1000 people diagnosed with peripheral T-cell lymphoma (PTCL) to see how different genetic subtypes affect disease progression and treatment response. Researchers will collect data from multiple hospitals and use genetic testing to classify patients. The goa…